(ARE) Alexandria Real Estate - Ratings and Ratios
Laboratories, Offices, Campuses, Venture Capital
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 9.86% |
| Yield on Cost 5y | 3.93% |
| Yield CAGR 5y | 5.18% |
| Payout Consistency | 92.1% |
| Payout Ratio | 2.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 51.9% |
| Value at Risk 5%th | 80.3% |
| Relative Tail Risk | -5.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.71 |
| Alpha | -60.58 |
| CAGR/Max DD | -0.39 |
| Character TTM | |
|---|---|
| Hurst Exponent | |
| Beta | 0.793 |
| Beta Downside | 1.136 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.19% |
| Mean DD | 32.37% |
| Median DD | 29.85% |
Description: ARE Alexandria Real Estate October 31, 2025
Alexandria Real Estate Equities (NYSE: ARE) is a S&P 500 life-science REIT that owns, operates, and develops “Megacampus” clusters in premier biotech hubs such as Boston, the Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. As of 30 June 2025 the company’s market cap is roughly $25.7 billion and it controls about 39.7 million rentable square feet (RSF) of operating space plus an additional 4.4 million RSF of Class A/A+ assets under construction, with one fully pre-leased project slated to break ground within the next year.
Key performance indicators from the most recent quarterly release show an occupancy rate near 96 % and a funds-from-operations (FFO) growth of 7 % year-over-year, driven by strong lease-rate escalations (≈5 % YoY) and a tenant mix weighted toward high-margin biotech and pharma firms. The REIT’s leverage remains moderate at roughly 45 % debt-to-EBITDA, reflecting its disciplined underwriting. Sector-wide, the life-science real-estate market is buoyed by a 12 % annual increase in U.S. biotech venture capital funding and sustained federal R&D spending, which together underpin demand for premium lab and office space.
For a deeper quantitative comparison of Alexandria’s valuation metrics against peers, the ValueRay platform offers a convenient dashboard for further analysis.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-413.1m TTM) > 0 and > 6% of Revenue (6% = 179.7m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -84.52% (prev -55.26%; Δ -29.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.38b > Net Income -413.1m (YES >=105%, WARN >=100%) |
| Net Debt (13.38b) to EBITDA (1.25b) ratio: 10.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (170.1m) change vs 12m ago -1.12% (target <= -2.0% for YES) |
| Gross Margin 68.94% (prev 70.57%; Δ -1.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 7.90% (prev 7.87%; Δ 0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.52 (EBITDA TTM 1.25b / Interest Expense TTM 216.7m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 59.47
| 1. Piotroski 2.50pt |
| 2. FCF Yield 6.21% |
| 3. FCF Margin 45.93% |
| 4. Debt/Equity 0.84 |
| 5. Debt/Ebitda 10.74 |
| 6. ROIC - WACC (= -3.94)% |
| 7. RoE -2.39% |
| 8. Rev. Trend 89.21% |
| 9. EPS Trend 6.70% |
What is the price of ARE shares?
Over the past week, the price has changed by +8.20%, over one month by -31.21%, over three months by -32.67% and over the past year by -49.03%.
Is ARE a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 73.5 | 37.2% |
| Analysts Target Price | 73.5 | 37.2% |
| ValueRay Target Price | 45.6 | -14.9% |
ARE Fundamental Data Overview November 20, 2025
P/E Forward = 16.6945
P/S = 2.8706
P/B = 0.5281
P/EG = 844.2
Beta = 1.324
Revenue TTM = 3.00b USD
EBIT TTM = -112.7m USD
EBITDA TTM = 1.25b USD
Long Term Debt = 12.04b USD (from longTermDebt, last quarter)
Short Term Debt = 1.55b USD (from shortTermDebt, last quarter)
Debt = 13.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.38b USD (from netDebt column, last quarter)
Enterprise Value = 22.16b USD (8.78b + Debt 13.96b - CCE 579.5m)
Interest Coverage Ratio = -0.52 (Ebit TTM -112.7m / Interest Expense TTM 216.7m)
FCF Yield = 6.21% (FCF TTM 1.38b / Enterprise Value 22.16b)
FCF Margin = 45.93% (FCF TTM 1.38b / Revenue TTM 3.00b)
Net Margin = -13.79% (Net Income TTM -413.1m / Revenue TTM 3.00b)
Gross Margin = 68.94% ((Revenue TTM 3.00b - Cost of Revenue TTM 930.5m) / Revenue TTM)
Gross Margin QoQ = 68.18% (prev 69.56%)
Tobins Q-Ratio = 0.59 (Enterprise Value 22.16b / Total Assets 37.38b)
Interest Expense / Debt = 0.39% (Interest Expense 54.9m / Debt 13.96b)
Taxrate = 21.0% (US default 21%)
NOPAT = -89.1m (EBIT -112.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.27 (Total Current Assets 945.2m / Total Current Liabilities 3.48b)
Debt / Equity = 0.84 (Debt 13.96b / totalStockholderEquity, last quarter 16.64b)
Debt / EBITDA = 10.74 (Net Debt 13.38b / EBITDA 1.25b)
Debt / FCF = 9.72 (Net Debt 13.38b / FCF TTM 1.38b)
Total Stockholder Equity = 17.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.11% (Net Income -413.1m / Total Assets 37.38b)
RoE = -2.39% (Net Income TTM -413.1m / Total Stockholder Equity 17.29b)
RoCE = -0.38% (EBIT -112.7m / Capital Employed (Equity 17.29b + L.T.Debt 12.04b))
RoIC = -0.29% (negative operating profit) (NOPAT -89.1m / Invested Capital 30.35b)
WACC = 3.64% (E(8.78b)/V(22.74b) * Re(8.94%) + D(13.96b)/V(22.74b) * Rd(0.39%) * (1-Tc(0.21)))
Discount Rate = 8.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 66.50% ; FCFE base≈1.33b ; Y1≈874.9m ; Y5≈400.1m
Fair Price DCF = 39.34 (DCF Value 6.80b / Shares Outstanding 172.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 6.70 | EPS CAGR: -3.88% | SUE: 0.62 | # QB: 0
Revenue Correlation: 89.21 | Revenue CAGR: 7.32% | SUE: -0.15 | # QB: 0
Additional Sources for ARE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle